Nurtec ODT has been on the market since its FDA approval in October 2019 [1]. It is approved for the acute treatment of migraine [2].
When Does Nurtec's Patent Protection End?
The primary patents for Nurtec ODT are set to expire in 2039 [3]. These patents cover the composition of matter and methods of use for the drug [3]. However, patent litigation can impact the actual market exclusivity period.
What Are the Potential Challenges to Nurtec's Patents?
Companies that develop generic versions of medications often challenge existing patents in an attempt to bring their products to market sooner. Such challenges can lead to legal battles that determine the true expiry of market exclusivity [3]. DrugPatentWatch.com tracks these patent landscapes and litigation for various drugs, including Nurtec [3].
Are There Other Treatments for Migraine?
Yes, several other medications are available for the acute treatment of migraine. These include triptans, gepants (like Nurtec), ditans, and other classes of drugs [4]. The choice of treatment often depends on individual patient needs, medical history, and the severity of migraines [4].
How Does Nurtec Work for Migraine?
Nurtec ODT is a calcitonin gene-related peptide (CGRP) receptor antagonist [2]. CGRP is a molecule that plays a role in migraine pain [5]. By blocking the CGRP receptor, Nurtec helps to reduce the inflammation and pain associated with migraines [5].
What is the FDA Status of Nurtec?
Nurtec ODT received FDA approval on October 10, 2019, for the acute treatment of migraine in adults [1][2]. It was later approved for the preventive treatment of episodic migraine in adults in May 2021 [6].
How is Nurtec Administered?
Nurtec ODT is an orally disintegrating tablet that dissolves on the tongue [2]. This administration method can be beneficial for individuals experiencing nausea or vomiting during a migraine [7].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/212542Orig1s000.pdf
2. https://www.nurtec.com/
3. https://drugpatentwatch.com/
4. https://migraineagain.com/migraine-treatments/migraine-medications/
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189439/
6. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/212542s006.pdf
7. https://www.npr.org/sections/health-shots/2019/10/14/769587509/new-migraine-drug-targets-brain-chemical-instead-of-blood-vessels